Alzheimer's disease CSF biomarkers: clinical indications and rational use.
about
Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice.Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.Multifunctionalized Reduced Graphene Oxide Biosensors for Simultaneous Monitoring of Structural Changes in Amyloid-β 40.Callosal circularity as an early marker for Alzheimer's disease.Diagnosis of neurodegenerative dementia: where do we stand, now?
P2860
Alzheimer's disease CSF biomarkers: clinical indications and rational use.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Alzheimer's disease CSF biomarkers: clinical indications and rational use.
@en
type
label
Alzheimer's disease CSF biomarkers: clinical indications and rational use.
@en
prefLabel
Alzheimer's disease CSF biomarkers: clinical indications and rational use.
@en
P2860
P921
P1476
Alzheimer's disease CSF biomarkers: clinical indications and rational use
@en
P2093
Maria Bjerke
Sara Valckx
P2860
P2888
P304
P356
10.1007/S13760-017-0816-5
P5008
P577
2017-07-27T00:00:00Z